Allergy News

SAN DIEGO -- An oral immunotherapy regimen can help take the sting out of severe peanut allergies, reported investigators here.

Five of seven children with severe peanut allergy were able, after two years of immunotherapy, to tolerate a dose of 7.8 grams of peanut flour, equivalent to eating more than 13 peanuts, reported Scott David Nash, M.D., of Duke in Durham, N.C., and colleagues.

Yet while oral immunotherapy can desensitize patients to peanuts, children who undergo it may not be in the clear, cautioned the authors in a featured poster session at the annual meeting of the American Academy of Allergy, Asthma & Immunology here.

Continue reading "AAAAI: Oral Immunotherapy Dampens But May Not Cure Peanut Allergy" »

Children who start drinking fresh milk from the farm early on are less likely to develop allergies when they are of school age, according to Swiss scientists.

But why more people are suffering allergies remains unclear, say researchers at Basel University, who have begun a study involving more than 14,000 children.

Cows' milk as food for infants has a bad reputation. From a nutritional perspective it does not fulfil the dietary requirements of babies, and children who are fed only cows' milk for too long often suffer an iron deficiency.

Continue reading "Cows' milk can protect against asthma" »

A fresh study by the Environmental Health section of the National Public Health Institute shows a strong link between asthma in children and dampness in the building structures of the home.

According to an article in the upcoming edition of the European Respiratory Journal, at least one in ten, and possibly as many as one in five cases of asthma among children are linked with water damage in the building.

The onset of asthma is the result of the cumulative effect of many factors. Nevertheless, in the 1990s there was a rapid increase in cases of asthma in Finland, as well as an increase in damage caused by dampness in buildings.

Continue reading "Finnish study links child asthma with structural dampness in buildings" »

The Berkeley-based company said it will explore developing a different path for trials for the treatment, called Tolamba.

It announced Jan. 8 that trials for the drug were inconclusive, sending shares of the company's stock that day down 30 percent to just below $6.

"It's not the death knell for the allergy program," said Shari Annes, a Dynavax spokeswoman. "It was an inconclusive trial, not a failed drug."

Continue reading "Dynavax drops allergy drug trials" »

The prescription antihistamine Astelin(R) (azelastine HCl) Nasal Spray(R) relieved the major symptoms of pollen allergy, including sneezing, runny nose and congestion, within 15 minutes of application compared to placebo and maintained efficacy at all time points for 8 hours in a randomized, single dose, double-blind, placebo- controlled study, MedPointe Pharmaceuticals announced today.

In addition, a group of patients treated with intranasal Nasonex(R) (mometasone furoate monohydrate) did not show symptom improvement compared to placebo during the eight hour study period. Data from the 450-patient study, conducted in a controlled environmental exposure unit (EEU), were presented at the 2007 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California.

Continue reading "Steroid-Free Astelin Nasal Spray Demonstrated Seasonal Allergy Symptom Improvement Within 15 Minutes in Clinical Study" »

The agency said it's asked the company to put a black-box warning label on the drug, which is sold under the brand name Xolair. A black box warning is the FDA's strongest warning.

Xolair was approved in 2003 to treat adults and adolescents with moderate to severe persistent asthma related to allergies whose symptoms are inadequately controlled with inhaled steroids.

A company spokesman couldn't immediately be reached.

Genentech shares recently rose 8 cents to $87.02.

Copyright (c) 2007 Dow Jones & Company, Inc.

Newswise — Children in this country suffer from asthma more than any other chronic illness, and new research finds African-American children with the condition have a greater risk than others of experiencing severe symptoms that escalate into an emergency.

Previous research has shown that in comparison with white and Hispanic children, African-Americans have a higher rate of asthma, are hospitalized more and face more disability due to the condition. Because of this, “we suspected they might also exhibit relatively more severe asthma symptoms at the time of hospitalization,” said Yu Bai, a doctoral candidate at Pennsylvania State University.

Bai and his colleagues analyzed the records of 7,726 white, African-American and Hispanic children up to age 19 who were admitted to Pennsylvania hospitals in 2001 for asthma symptoms. The researchers then examined how the physician reported the severity of the children’s condition and ranked them either as “emergency” or “non-emergency” admissions.

Continue reading "Race May Play a Role in Children’s Asthma Care" »

British scientists reported last spring in the journal Nature Genetics that people who suffer from both eczema and asthma carry the same gene mutation and concluded that in some cases eczema may actually lead to asthma.

Continue reading "Cracked skin could be path to asthma" »